Quick Answer
TScan Therapeutics, Inc. reported Net Income of -$129.77 million for fiscal year 2025.
TScan Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$129.77M | -1.8% |
| 2024 | -$127.50M | -42.9% |
| 2023 | -$89.22M | -34.7% |
| 2022 | -$66.22M | -36.2% |
| 2021 | -$48.62M | -86.1% |
| 2020 | -$26.13M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$35.71M | -19.5% | +3.4% |
| June 30, 2025 | -$36.95M | -16.7% | -8.3% |
| March 31, 2025 | -$34.13M | -13.2% | -14.2% |
| September 30, 2024 | -$29.89M | -30.0% | +5.6% |
| June 30, 2024 | -$31.66M | -31.7% | -5.0% |
| March 31, 2024 | -$30.14M | -33.6% | -31.1% |
| September 30, 2023 | -$23.00M | -41.6% | +4.4% |
| June 30, 2023 | -$24.05M | -59.3% | -6.6% |
- TScan Therapeutics, Inc. showed a decrease of -1.8% in Net Income compared to the prior fiscal year.
- Over the 2020–2025 period, TScan Therapeutics, Inc.’s net income has declined by 396.7% (from -$26.13 million to -$129.77 million).
- The most recent figure is from TScan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 4, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: